基石药业-B(02616.HK)遭非执行董事胡正国减持22.3万股
CSTONE PHARMACSTONE PHARMA(HK:02616) Ge Long Hui·2025-09-11 06:20

Group 1 - The core point of the article is that Hu Zhengguo, a non-executive director of Basetone Pharmaceuticals-B (02616.HK), reduced his shareholding by selling 223,000 shares at an average price of HKD 12.007 per share, amounting to approximately HKD 2.678 million [1] - After the sale, Hu Zhengguo's total shareholding decreased to 2.471 million shares, with his ownership percentage dropping from 0.18% to 0.17% [1] Group 2 - Basetone Pharmaceuticals-B (02616.HK) granted a total of 4.8 million stock options [2]